Genentech maintains a presence at in-person and virtual scientific congresses worldwide. Find Genentech-sponsored posters and presentations from recent congresses at Medically.gene.com.

Clinical Trials

Find information about active clinical research for Genentech rare blood disorder portfolio products.

Hemlibra^® at ClinicalTrials.gov

Additional Resources

Connect with a Medical Science Liaison

Browse the Genentech Medical Information Library

Visit emicizumabinfo.com, a different Genentech medical website, for key Hemlibra^® safety topics

Thank you for visiting Genentech Medical and Scientific Information

Stay here

You can find out more about your selected topic at Medically, a different Genentech Medical website which includes information about investigational compounds and uses. The information presented does not imply US FDA approval and should not be construed as a recommendation for use. Do you wish to proceed?

Stay here

Abbreviations

A to F

Ab: antibody
AE: adverse event
ASTCT: American Society for Transplantation and Cellular Therapy
CR: complete response
CRS: cytokine release syndrome
CT: computed tomography
CTCAE: Common Terminology Criteria for Adverse Events
DoR: duration of response
ECOG PS: Eastern Cooperative Oncology Group performance status
FL: follicular lymphoma

I to U

ICANS: immune effector cell-associated neurotoxicity syndrome
IRF: independent review facility
IV: intravenous
IQR: interquartile range
NCI CTCAE: National Center Institute Common Terminology Criteria for Adverse Events
NHL: non-Hodgkin lymphoma
ORR: objective response rate
PET: positron emission tomography
PFS: progression-free survival
PR: partial response
R/R: relapsed/refractory
SAE: serious adverse event
SD: stable disease
USPI: United States Prescribing Information
UTI: urinary tract infection

Our Rare Blood Disorder Portfolio

H

Hemlibra®

Publications

Scientific Congresses

Clinical Trials

Additional Resources

Hemlibra^®